Lupin bags USFDA nod for pregnancy prevention drug Minzoya
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy.
Mumbai: Global pharma major Lupin Limited today announced that the Company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets), 0.1 mg/0.02 mg and 36.5 mg, to market a generic equivalent of Balcoltra (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) 0.1 mg/0.02 mg and 36.5 mg, of Avion Pharmaceuticals LLC.
The product will be manufactured at Lupin’s Pithampur facility in India.
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy.
Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets (RLD Balcoltra) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT December 2023).
Read also: Lupin unveils Ganirelix Acetate Injection in US
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.
Read also: Lupin unveils Bromfenac Ophthalmic Solution, 0.075% in US
